ResMed Launches Cloud-Based Health Solutions Across Europe
London, Friday, 7 February 2025.
ResMed unveils cloud-connected devices in Europe, enhancing care for sleep apnea and chronic diseases through remote monitoring and data analysis, aiming to reduce hospitalizations.
Digital Health Expansion
Building on its strong financial performance in Q2 2025, with reported revenues of $1.282 billion [4], ResMed is strategically expanding its digital health footprint in Europe. The company, which operates in over 140 countries [1], is leveraging its expertise in sleep apnea and COPD treatment through the integration of its AirView platform, enabling healthcare professionals to monitor patient therapy data remotely [1].
Advanced Technology Integration
At the heart of this European rollout is ResMed’s AirSense 10 AutoSet device, featuring advanced capabilities including auto-adjusting technology and built-in wireless connectivity [2]. The device, which maintains a noise level of just 25 dB [2], seamlessly integrates with the myAir app, providing patients with direct access to their therapy data and personalized coaching tips [1].
Patient Impact and Outcomes
The impact of ResMed’s technology on patient care is already evident through user experiences. As demonstrated by patient Dave Whelan, who experienced significant improvements in his daily life after beginning treatment [1]. The company’s focus on remote monitoring capabilities is particularly timely, aligning with the growing convergence of consumer and health technology to enable more personalized care delivery [1].
Future Growth and Innovation
ResMed’s commitment to innovation is reflected in its substantial R&D investment, with approximately 19% of its workforce dedicated to research and development [4]. The company’s expansion in Europe comes as part of its broader strategy to enhance its Software as a Service (SaaS) and digital health applications, with a particular focus on artificial intelligence and machine learning for product enhancement [4]. With an adjusted gross margin of 59.2% [4], ResMed is well-positioned to continue its investment in digital health solutions that transform patient care across Europe.